Median Technologies
Company Profile
Business description
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.
Contact
1800 Route Des Cretes
Les Deux Arcs B
Valbonne06560
FRAT: +33 493333777
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
211
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,121.07 | 36.22 | -0.44% |
| DAX 40 | 23,958.30 | 160.59 | -0.67% |
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% |
| FTSE 100 | 9,717.25 | 42.81 | -0.44% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,724.96 | 143.81 | 0.61% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,840.20 | 17.86 | 0.26% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |